Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so far in 2026, per BioPharma Dive data.
Source: BioPharma Dive
You may also like
Vera Therapeutics wins FDA nod for closely watched...
Gene editing developer Scribe plots an IPO
Novartis to pay $1.1B upfront for UK biotech Myricx to...
Genentech lays off 103 alongside gRED rethink, pens...
Scribe notes down IPO ambition to fund lipid-lowering...
Exact Imaging boosts U.S. commercial team for next-gen...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.